Can p63 serve as a biomarker for diagnosing giant cell tumor of bone? A systematic review and meta-analysis
Keywords:
Biomarkers, Diagnosis, Giant cell tumor of boneAbstract
BACKGROUND: Tumor protein p63 (p63) has been reported to be highly expressed in giant cell tumor of bone (GCTB). Whether p63 can be treated as a diagnostic marker for GCTB remains unclear. OBJECTIVE: We conducted a meta-analysis to evaluate the applicability of p63 in diagnosing GCTB. DESIGN AND SETTING: Systematic review and meta-analysis carried out in a public hospital, Hong Kong, China. METHODS: We searched PubMed, EMBASE and the Cochrane Library from inception to April 30, 2019. Literature in English or Chinese about the differential diagnosis of GCTB using p63 were included. Animal experiments, reviews, correspondence, case reports, expert opinions and editorials were excluded. Studies were also excluded if they did not provide sufficient information to construct a 2 × 2 contingency table. We calculated individual and pooled sensitivities and specificities. We used I² as an indicator of heterogeneity. RESULTS: Out of 88 records identified, 8 articles on 788 GCTB patients fulfilled the inclusion criteria and were included in the present analysis. Bivariate analyses yielded a pooled mean sensitivity of 0.87 (95% confidence interval, CI, 0.72-0.95) and specificity of 0.71 (95% CI, 0.56-0.82) for using p63 as a biomarker in diagnosing GCTB. The area under the receiver operating characteristic curve was 0.86 (95% CI, 0.82-0.88). CONCLUSION: p63 is a helpful indicator in diagnosing GCTB due to its high sensitivity and specificity. Nonetheless, the results need to be carefully interpreted based on other diagnostic methods such as imaging. SYSTEMATIC REVIEW REGISTRATION: 164115 (PROSPERO registration number)
Downloads
References
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011 Feb;469(2):591-9. PMID: 20706812; doi: 10.1007/s11999-010-1501-7.
Mello GP, Sonehara HA, Neto MA. Cementless endoprosthesis in the treatment of giant cell tumor of the tibia: eighteen years of evolution. Rev Bras Ortop. 2015;45(6):612-7. PMID: 27026973; doi: 10.1016/S2255-4971(15)30312-8.
Wülling M, Engels C, Jesse N, et al. The nature of giant cell tumor of bone. J Cancer Res Clin Oncol. 2001;127(8):467-74. PMID: 11501745; doi: 10.1007/s004320100234.
Amary F, Berisha F, Ye H, et al. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone. Am J Surg Pathol. 2017;41(8):1059-68. PMID: 28505000; doi: 10.1097/PAS.0000000000000859.
Turcotte RE, Wunder JS, Isler MH, et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res. 2002;(397):248-58. PMID: 11953616; doi: 10.1097/00003086-200204000-00029
Jeys LM, Suneja R, Chami G, et al. Impending fractures in giant cell tumours of the distal femur: incidence and outcome. Int Orthop. 2006;30(2):135-8. PMID: 16474936; doi: 10.1007/s00264-005-0061-z.
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res. 2011;469(4):1181-7. PMID: 20857250; doi: 10.1007/s11999-010-1560-9.
Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor. Skeletal Radiol. 2003;32(3):143-6. PMID: 12605278; doi: 10.1007/s00256-002-0550-8.
Fazioli F, Battaglini G, Marescotti G, Perna G. Pulmonary metastasis of giant cell tumor. Chir Organi Mov. 1995;80(1):91-4. PMID: 7641547.
Miller IJ, Blank A, Yin SM, et al. A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases. Diagn Pathol. 2010;5:62. PMID: 20860830; doi: 10.1186/1746-1596-5-62.
Pereira HM, Marchiori E, Severo A. Magnetic resonance imaging aspects of giant-cell tumours of bone. J Med Imaging Radiat Oncol. 2014;58(6):674-8. PMID: 25256094; doi: 10.1111/1754-9485.12249.
Santini-Araujo E, Kalil RK, Bertoni F, Park YK. Tumors and Tumor-Like Lesions of Bone: For Surgical Pathologists, Orthopedic Surgeons and Radiologists. New York: Springer; 2015. doi: 10.1007/978-1-4471-6578-1.
Singh AS, Chawla NS, Chawla SP. Giant-cell tumor of bone: treatment options and role of denosumab. Biologics. 2015;9:69-74. PMID: 26203221; doi: 10.2147/BTT.S57359.
Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am. 2006;37(1):35-51. PMID: 16311110; doi: 10.1016/j.ocl.2005.08.005.
Yanagisawa M, Okada K, Tajino T, et al. A clinicopathological study of giant cell tumor of small bones 2011;116(4):265-8. PMID: 21919814; doi: 10.3109/03009734.2011.596290.
van der Heijden L, Dijkstra PD, van de Sande MA, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014;19(5):550-61. PMID: 24718514; doi: 10.1634/theoncologist.2013-0432.
Puri A, Agarwal MG, Shah M, et al. Giant cell tumor of bone in children and adolescents. J Pediatr Orthop. 2007;27(6):635-9. PMID: 17717462; doi: 10.1097/BPO.0b013e3181425629.
Shooshtarizadeh T, Rahimi M, Movahedinia S. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions. Pathol Res Pract. 2016;212(10):876-9. PMID: 27473669; doi: 10.1016/j.prp.2016.07.007.
Yanagisawa M, Kakizaki H, Okada K, Torigoe T, Kusumi T. p63 as a prognostic marker for giant cell tumor of bone. 2013:118(1):23-8. PMID: 23033898; doi: 10.3109/03009734.2012.724731.
Lee CH, Espinosa I, Jensen KC, et al. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol. 2008;21(5):531-9. PMID: 18192965; doi: 10.1038/modpathol.3801023.
Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982-90. PMID: 16168343; doi: 10.1016/j.jclinepi.2005.02.022.
Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol. 2006;59(12):1331-2. PMID: 17098577; doi: 10.1016/j.jclinepi.2006.06.011.
Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. Stat Med. 1993;12(24):2273-84. PMID: 7907813; doi: 10.1002/sim.4780122405.
van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21(4):589-624. PMID: 11836738; doi: 10.1002/sim.1040.
Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):883-93. PMID: 16085191; doi: 10.1016/j.jclinepi.2005.01.016.
de la Roza G. p63 expression in giant cell-containing lesions of bone and soft tissue. Arch Pathol Lab Med. 2011;135(6):776-9. PMID: 21631272; doi: 10.1043/2010-0291-OA.1.
Hammas N, Laila C, Youssef AL, et al. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience. Diagn Pathol. 2012;7:130. PMID: 23016917; doi: 10.1186/1746-1596-7-130.
Maues De Paula A, Vasiljevic A, Giorgi R, et al. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50% of cells is stained. Virchows Arch. 2014;465(4):487-94. PMID: 25100342; doi: 10.1007/s00428-014-1637-z.
Dickson BC, Li S, Wunder JS, et al. Giant cell tumor of bone express p63. Mod Pathol. 2008;21(4):369-75. PMID: 18311114; doi: 10.1038/modpathol.2008.29.
Huang J, Jiang Z, Zhang H. Zhonghua Bing Li Xue Za Zhi. 2014;43(6):379-82. PMID: 25208987.
Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29(7):1043-51. PMID: 12734652; doi: 10.1007/s00134-003-1761-8.
